EGFR and non-small cell lung carcinoma: Clinical assessment of TAS6417 in NSCLC patients has not yet begun; therefore, it remains to be determined whether the mutant selectivity of the inhibitor is sufficient to achieve a good therapeutic window with low toxicity in EGFR exon 20 insertion-positive patients.